Literature DB >> 22911016

Potential role of cholinesterases to predict short-term outcome after hepatic resection for hepatocellular carcinoma.

Matteo Donadon1, Matteo Cimino, Fabio Procopio, Emanuela Morenghi, Marco Montorsi, Guido Torzilli.   

Abstract

Estimation of functional liver reserve in patients with hepatocellular carcinoma (HCC) is of paramount importance to properly select candidates for surgical resection. Together with the value of bilirubin, the presence/absence of ascites and esophageal varices, and the rate of residual liver volume, which are our current parameters to measure functional liver reserve, we sought to investigate the value of preoperative cholinesterases (CHE) in predicting postoperative outcome after hepatic resection for HCC. We reviewed the records of 279 consecutive patients who underwent hepatic resection for HCC in our Unit between 2001 and 2011. The value of preoperative CHE was analyzed against the occurrence of postoperative events. Receiver-operator characteristic curve analysis was used to identify cut-off values of CHE that predicted adverse outcomes. Univariate and multivariate analyses on clinically relevant variables, which included the MELD score among others, were performed. P < 0.05 was considered statistically significant. Eighty (29 %) of 279 patients had complications, of which 60 (21.5 %) were liver-related. Major morbidity occurred in 16 (6 %) patients. The 30-day postoperative mortality was 1 %. A value of CHE ≤ 5,900 UI/L had a sensitivity of 73 % and a specificity of 67 % in predicting liver-related postoperative complications (P = 0.001). The multivariate analysis revealed that only blood transfusion, major resections, and a value of CHE ≤ 5,900 UI/L independently predicted the risk of morbidity. The results indicated that CHE contributed important information in predicting postoperative outcome after hepatic resection for HCC. Thus, it should be included in the selection process of candidates to surgery for such disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22911016     DOI: 10.1007/s13304-012-0174-z

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  32 in total

1.  Bilirubin level fluctuation in drain discharge after hepatectomies justifies long-term drain maintenance.

Authors:  Guido Torzilli; Natale Olivari; Daniele Del Fabbro; Andrea Gambetti; Piera Leoni; Adele Gendarini; Masatoshi Makuuchi
Journal:  Hepatogastroenterology       Date:  2005 Jul-Aug

2.  Enzyme diagnosis of liver diseases.

Authors:  E Schmidt; F W Schmidt
Journal:  Clin Biochem       Date:  1993-08       Impact factor: 3.281

Review 3.  Biological function of cholinesterase.

Authors:  K M Kutty
Journal:  Clin Biochem       Date:  1980-12       Impact factor: 3.281

Review 4.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters.

Authors:  Mehmet Bektas; Ramazan Idilman; Irfan Soykan; Ender Soydan; Mutlu Arat; Kubilay Cinar; Sahin Coban; Ali Tuzun; Hakan Bozkaya; Necati Ormeci; Ali Ozden
Journal:  J Clin Gastroenterol       Date:  2008 May-Jun       Impact factor: 3.062

7.  Predictive indices of morbidity and mortality after liver resection.

Authors:  Rebecca A Schroeder; Carlos E Marroquin; Barbara Phillips Bute; Shukri Khuri; William G Henderson; Paul C Kuo
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

Review 8.  Hepatocellular carcinoma: current management and recent advances.

Authors:  Wan-Yee Lau; Eric C H Lai
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-06

9.  Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Norihiro Kokudo; Keiji Sano; Hiroshi Imamura; Yoshifumi Beck; Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2009-01

10.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

View more
  8 in total

1.  Is Postoperative Adjuvant Transcatheter Arterial Infusion Therapy Effective for Patients with Hepatocellular Carcinoma who Underwent Hepatectomy? A Prospective Randomized Controlled Trial.

Authors:  Fumitoshi Hirokawa; Koji Komeda; Kohei Taniguchi; Mitsuhiro Asakuma; Tetsunosuke Shimizu; Yoshihiro Inoue; Shuji Kagota; Atsushi Tomioka; Kazuhiro Yamamoto; Kazuhisa Uchiyama
Journal:  Ann Surg Oncol       Date:  2020-06-04       Impact factor: 5.344

2.  Diagnosis and Management of Bile Leaks After Hepatectomy: Results of a Prospective Analysis of 475 Hepatectomies.

Authors:  Matteo Donadon; Guido Costa; Matteo Cimino; Fabio Procopio; Daniele Del Fabbro; Angela Palmisano; Guido Torzilli
Journal:  World J Surg       Date:  2016-01       Impact factor: 3.352

3.  Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score.

Authors:  Matteo Donadon; Guido Costa; Matteo Cimino; Fabio Procopio; Daniele Del Fabbro; Angela Palmisano; Guido Torzilli
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

Review 4.  Resection for Klatskin tumors: technical complexities and results.

Authors:  Ivan Capobianco; Jens Rolinger; Silvio Nadalin
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-18

5.  Effect of liver resection-induced increases in hepatic venous pressure gradient on development of postoperative acute kidney injury.

Authors:  Christian Reiterer; Alexander Taschner; Florian Luf; Manfred Hecking; Dietmar Tamandl; Oliver Zotti; Thomas Reiberger; Patrick Starlinger; Mattias Mandorfer; Edith Fleischmann
Journal:  BMC Nephrol       Date:  2022-01-08       Impact factor: 2.388

6.  An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.

Authors:  Shan Lu; Ziqi Meng; Yingying Tan; Chao Wu; Zhihong Huang; Jiaqi Huang; Changgeng Fu; Antony Stalin; Siyu Guo; Xinkui Liu; Leiming You; Xiaojiaoyang Li; Jingyuan Zhang; Wei Zhou; Xiaomeng Zhang; Miaomiao Wang; Jiarui Wu
Journal:  BMC Complement Med Ther       Date:  2022-03-02

7.  High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in Chinese patients.

Authors:  Jia-Hui Qi; Jin Wang; Jinyun Chen; Fan Shen; Jing-Tao Huang; Subrata Sen; Xin Zhou; Song-Mei Liu
Journal:  BMC Cancer       Date:  2014-08-31       Impact factor: 4.430

8.  Monitoring of liver function in a 73-year old patient undergoing 'Associating Liver Partition and Portal vein ligation for Staged hepatectomy': case report applying the novel liver maximum function capacity test.

Authors:  Felix Oldhafer; Kristina I Ringe; Kai Timrott; Moritz Kleine; Wolf Ramackers; Sebastian Cammann; Mark D Jäger; Juergen Klempnauer; Hueseyin Bektas; Florian W R Vondran
Journal:  Patient Saf Surg       Date:  2016-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.